CAMBRIDGE, Mass., Jan. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today ...
Nuvalent, Inc., a clinical-stage biopharmaceutical company, announced the initiation of the phase 2 portion of ALKOVE-1, its phase 1/2 clinical trial of NVL-655 for patients with ALK-positive ...
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback